Kissing goodbye to key opinion leaders

Ray N Moynihan
Med J Aust 2012; 196 (11): . || doi: 10.5694/mja12.10538
Published online: 18 June 2012

Drug industry report reveals strained relations with medical “thought leaders”

One of the hottest topics in the business of medicine is how the new sunshine of disclosure is affecting relations between drug companies and so-called key opinion leaders, or KOLs. In the United States, growing public scrutiny of company payments is now causing many doctors to shy away from corporate invitations to consult, speak or advise. As greater transparency comes to Australia, and previously hidden dealings are put on the table, industry here may also have to kiss goodbye to a key component of its marketing machinery.

  • Byron Bay, NSW.

Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.